{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T06:11:39Z","timestamp":1776147099626,"version":"3.50.1"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                      is a leading cause of healthcare-associated infections in immunocompromised patients and frequently exhibits multidrug resistance. Cefiderocol, a siderophore cephalosporin, is among the few remaining therapeutic options for infections caused by carbapenem-resistant\n                      <jats:italic>A. baumannii<\/jats:italic>\n                      (CRAB); however, its activity may differ by clonal lineage and can be further compromised in the biofilm state. This study investigates genomic features and cefiderocol efficacy against planktonic and biofilm-associated forms of oncology-derived\n                      <jats:italic>A. baumannii<\/jats:italic>\n                      isolates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Twenty-five non-duplicate, consecutive clinical isolates of\n                      <jats:italic>A. baumannii<\/jats:italic>\n                      from oncology patients underwent whole-genome sequencing and multilocus sequence typing. Cefiderocol activity was quantified in planktonic and biofilm-associated states using minimum bactericidal concentration (MBC) and minimum biofilm eradication concentration (MBEC) assays.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ten sequence types were identified, with the high-risk sequence type 2 (ST2) clone accounting for 56% (14\/25) of isolates. ST2 strains showed significantly higher resistance to aminoglycosides, carbapenems, and fluoroquinolones than non-ST2 (NST) strains. The carbapenemase gene\n                      <jats:italic>bla<\/jats:italic>\n                      <jats:sub>OXA\u221223<\/jats:sub>\n                      was detected exclusively in ST2. Colistin and cefiderocol were the most active agents overall. ST2 strains showed higher cefiderocol MBC values than NST strains. However, avibactam significantly reduced cefiderocol MBC in ST2, consistent with class D \u03b2-lactamases activity. ST2 and NST isolates exhibited comparable distributions of iron acquisition genes and similar CAS-detected siderophore activity under the assay conditions tested. Cefiderocol activity was significantly reduced in biofilms relative to planktonic cells (median MBEC 2 \u00b5g\/ml versus median MBC 0.5 \u00b5g\/ml). NST exhibited higher MBEC\/MBC ratios than ST2 isolates, indicating greater biofilm-associated tolerance to cefiderocol.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>\n                      Collectively, these data associate the predominance of oncology-derived ST2 with\n                      <jats:italic>bla<\/jats:italic>\n                      <jats:sub>OXA-23<\/jats:sub>\n                      carriage and higher cefiderocol bactericidal thresholds and show that cefiderocol activity is consistently reduced in the biofilm state. Future studies integrating functional measures of iron acquisition and \u03b2-lactamase activity will be needed to define the determinants of cefiderocol efficacy across lineages and growth states.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2026.1788718","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:36:02Z","timestamp":1776144962000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clonal lineage and biofilm growth shape cefiderocol activity in Acinetobacter baumannii from oncology patients"],"prefix":"10.3389","volume":"16","author":[{"given":"Ilaria","family":"Cavallo","sequence":"first","affiliation":[{"name":"Microbiology and Virology, San Gallicano Dermatological Institute, IRCCS","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Sivori","sequence":"additional","affiliation":[{"name":"Microbiology and Virology, San Gallicano Dermatological Institute, IRCCS","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Truglio","sequence":"additional","affiliation":[{"name":"Microbiology and Virology, San Gallicano Dermatological Institute, IRCCS","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Francalancia","sequence":"additional","affiliation":[{"name":"Microbiology and Virology, San Gallicano Dermatological Institute, IRCCS","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elva","family":"Abril","sequence":"additional","affiliation":[{"name":"Microbiology and Virology, San Gallicano Dermatological Institute, IRCCS","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Fabrizio","sequence":"additional","affiliation":[{"name":"Department of Biology and Biotechnology \u201cC. Darwin\u201d, Sapienza University of Rome","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Petrolo","sequence":"additional","affiliation":[{"name":"Microbiology and Virology, San Gallicano Dermatological Institute, IRCCS","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Maione","sequence":"additional","affiliation":[{"name":"Microbiology and Virology, San Gallicano Dermatological Institute, IRCCS","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grazia","family":"Prignano","sequence":"additional","affiliation":[{"name":"Microbiology and Virology, San Gallicano Dermatological Institute, IRCCS","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Mastrofrancesco","sequence":"additional","affiliation":[{"name":"Microbiology and Virology, San Gallicano Dermatological Institute, IRCCS","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulvia","family":"Pimpinelli","sequence":"additional","affiliation":[{"name":"Microbiology and Virology, San Gallicano Dermatological Institute, IRCCS","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enea Gino","family":"Di Domenico","sequence":"additional","affiliation":[{"name":"Microbiology and Virology, San Gallicano Dermatological Institute, IRCCS","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02646-20","article-title":"In vitro antibacterial activity of cefiderocol against multidrug-resistant Acinetobacter baumannii","volume":"65","author":"Abdul-Mutakabbir","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.jamcollsurg.2006.06.013","article-title":"Impact of Acinetobacter infection on the mortality of burn patients","volume":"203","author":"Albrecht","year":"2006","journal-title":"J. Am. Coll. Surgeons"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1099\/mgen.0.001080","article-title":"Genomics of Acinetobacter baumannii iron uptake","volume":"9","author":"Artuso","year":"2023","journal-title":"Microb. Genomics"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100896","article-title":"Molecular and clinical epidemiology of carbapenem resistant Acinetobacter baumannii ST2 in Oceania: a multicountry cohort study","volume":"40","author":"Baleivanualala","year":"2023","journal-title":"Lancet Regional Health - Western Pacific"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2026.107718","article-title":"Resistance to sulbactam\/durlobactam in carbapenem-resistant Acinetobacter baumannii in treatment-naive setting: in vitro data and genomic insights from Italian bloodstream isolates","volume":"67","author":"Bianco","year":"2026","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaf134","article-title":"The global epidemiology of carbapenem-resistant Acinetobacter baumannii","volume":"7","author":"Boutzoukas","year":"2025","journal-title":"JAC-Antimicrob Resist."},{"key":"B7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jgar.2025.03.012","article-title":"Genomic insights of predominant international high-risk clone ST2 Acinetobacter baumannii isolates in Saudi Arabia","volume":"42","author":"Brek","year":"2025","journal-title":"J. Global Antimicrob. Resist."},{"key":"B8","doi-asserted-by":"publisher","first-page":"5825","DOI":"10.1093\/molbev\/msab293","article-title":"eggNOG-mapper v2: Functional annotation, orthology assignments, and domain prediction at the metagenomic scale","volume":"38","author":"Cantalapiedra","year":"2021","journal-title":"Mol. Biol. Evol."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1196774","article-title":"Acinetobacter baumannii in the critically ill: complex infections get complicated","volume":"14","author":"Cavallo","year":"2023","journal-title":"Front. Microbiol."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11070955","article-title":"Whole-genome sequencing of ST2 A. baumannii causing bloodstream infections in COVID-19 patients","volume":"11","author":"Cherubini","year":"2022","journal-title":"Antibiotics"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00471-25","article-title":"The impact of commercially available media on cefiderocol susceptibility testing by broth microdilution method","volume":"63","author":"DeJonge","year":"2025","journal-title":"J. Clin. Microbiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1093\/jac\/dkaa117","article-title":"Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia","volume":"75","author":"Delgado-Valverde","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1432883","article-title":"Efficacy of sodium hypochlorite in overcoming antimicrobial resistance and eradicating biofilms in clinical pathogens from pressure ulcers","volume":"15","author":"Fabrizio","year":"2024","journal-title":"Front. Microbiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jgar.2025.04.010","article-title":"Cefiderocol activity against planktonic and biofilm forms of \u03b2-lactamase-producing pseudomonas aeruginosa from people with cystic fibrosis","volume":"43","author":"Fabrizio","year":"2025","journal-title":"J. Global Antimicrob. Resist."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.00930","article-title":"Comparative analysis of the two Acinetobacter baumannii multilocus sequence typing (MLST) schemes","volume":"10","author":"Gaiarsa","year":"2019","journal-title":"Front. Microbiol."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0287211","article-title":"Prevalence of biofilm producing Acinetobacter baumannii clinical isolates: a systematic review and meta-analysis","volume":"18","author":"Gedefie","year":"2023","journal-title":"PloS One"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00310-16","article-title":"Global assessment of the activity of tigecycline against multidrug-resistant gram-negative pathogens between 2004 and 2014 as part of the tigecycline evaluation and surveillance trial","volume":"2","author":"Giammanco","year":"2017","journal-title":"mSphere"},{"key":"B19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/lam.12627","article-title":"Evaluation of the ability of Acinetobacter baumannii to form biofilms on six different biomedical relevant surfaces","volume":"63","author":"Greene","year":"2016","journal-title":"Lett. Appl. Microbiol."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02215-24","article-title":"Virulence profile of carbapenem-resistant Klebsiella pneumoniae strains by an in vivo model of Galleria mellonella","volume":"13","author":"Guembe","year":"2025","journal-title":"Microbiol. Spectr"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01968-17","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gram-negative bacilli collected worldwide in 2014 to 2016","volume":"62","author":"Hackel","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1093\/jac\/dkaf306","article-title":"Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms","volume":"80","author":"Halim","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1099\/mgen.0.000306","article-title":"Emergence, molecular mechanisms and global spread of carbapenem-resistant Acinetobacter baumannii","volume":"5","author":"Hamidian","year":"2019","journal-title":"Microb. Genomics"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1093\/molbev\/msx148","article-title":"Fast genome-wide functional annotation through orthology assignment by eggNOG-Mapper","volume":"34","author":"Huerta-Cepas","year":"2017","journal-title":"Mol. Biol. Evol."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms12122474","article-title":"Genomic investigation and comparative analysis of European high-risk clone of Acinetobacter baumannii ST2","volume":"12","author":"Hummel","year":"2024","journal-title":"Microorganisms"},{"key":"B26","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2217\/fmb-2016-0200","article-title":"Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in Greece: an extended review, (2000\u20132015)","volume":"12","author":"Karampatakis","year":"2017","journal-title":"Future Microbiol."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12121729","article-title":"Cefiderocol and sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii","volume":"12","author":"Karruli","year":"2023","journal-title":"Antibiotics"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12080975","article-title":"Extensive drug resistance of strong biofilm-producing Acinetobacter baumannii strains isolated from infections and colonization hospitalized patients in Southern Poland","volume":"12","author":"Kasperski","year":"2023","journal-title":"Pathogens"},{"key":"B29","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s40121-023-00773-6","article-title":"Cefiderocol, a siderophore cephalosporin, as a treatment option for infections caused by carbapenem-resistant Enterobacterales","volume":"12","author":"Kaye","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01474-24","article-title":"In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp. including \u03b2-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitals","volume":"12","author":"Kimbrough","year":"2024","journal-title":"Microbiol. Spectr"},{"key":"B31","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1128\/aem.46.1.165-170.1983","article-title":"Multiple antibiotic resistance indexing of Escherichia coli to identify high-risk sources of fecal contamination of foods","volume":"46","author":"Krumperman","year":"1983","journal-title":"Appl. Environ. Microbiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1097\/CCM.0000000000000125","article-title":"Risk factors and outcome analysis of Acinetobacter baumannii complex bacteremia in critical patients","volume":"42","author":"Lee","year":"2014","journal-title":"Crit. Care Med."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/femsre\/fuad050","article-title":"What\u2019s in a name? Characteristics of clinical biofilms","volume":"47","author":"Lichtenberg","year":"2023","journal-title":"FEMS Microbiol. Rev."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2023.2289769","article-title":"Pathogenicity and virulence of Acinetobacter baumannii: Factors contributing to the fitness in healthcare settings and the infected host","volume":"15","author":"Lucidi","year":"2024","journal-title":"Virulence"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms13102292","article-title":"Is increased biofilm formation associated with decreased antimicrobial susceptibility? A systematic literature review","volume":"13","author":"Madduri","year":"2025","journal-title":"Microorganisms"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s10096-023-04677-8","article-title":"Co-regulation of biofilm formation and antimicrobial resistance in Acinetobacter baumannii: from mechanisms to therapeutic strategies","volume":"42","author":"Mendes","year":"2023","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3201\/eid1601.090852","article-title":"Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii 1","volume":"16","author":"Mugnier","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1099\/mgen.0.001500","article-title":"Dominance of high-risk clones ST2 and ST571 and the diversity of resistance islands in clinical Acinetobacter baumannii isolates from Hanoi, Vietnam","volume":"11","author":"Nghiem","year":"2025","journal-title":"Microb. Genomics"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.mimet.2024.106972","article-title":"Comparison of available methods to evaluate cefiderocol susceptibility in Acinetobacter spp","volume":"223","author":"Pasteran","year":"2024","journal-title":"J. Microbiol. Methods"},{"key":"B40","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/0966-842X(93)90036-Q","article-title":"Iron acquisition in microbial pathogenesis","volume":"1","author":"Payne","year":"1993","journal-title":"Trends Microbiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1093\/jac\/dkp253","article-title":"In vitro activity of ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin and trimethoprim\/sulfamethoxazole against planktonic and sessile Burkholderia cepacia complex bacteria","volume":"64","author":"Peeters","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"B42","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1128\/CMR.00058-07","article-title":"Acinetobacter baumannii: Emergence of a successful pathogen","volume":"21","author":"Peleg","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.04505-22","article-title":"The COVID-19 pandemic sparked off a large-scale outbreak of carbapenem-resistant Acinetobacter baumannii from the endemic strains at an Italian hospital","volume":"11","author":"Petazzoni","year":"2023","journal-title":"Microbiol. Spectr"},{"key":"B44","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.cmi.2019.03.014","article-title":"Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment","volume":"25","author":"Piperaki","year":"2019","journal-title":"Clin. Microbiol. Infection"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01194-20","article-title":"Cefiderocol retains antibiofilm activity in multidrug-resistant gram-negative pathogens","volume":"65","author":"Pybus","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B46","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/j.1469-0691.2007.01916.x","article-title":"Biofilm formation in Acinetobacter baumannii: associated features and clinical implications","volume":"14","author":"Rodr\u00edguez-Ba\u00f1o","year":"2008","journal-title":"Clin. Microbiol. Infection"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.793615","article-title":"Convergence of biofilm formation and antibiotic resistance in Acinetobacter baumannii infection","volume":"9","author":"Roy","year":"2022","journal-title":"Front. Med."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00194-23","article-title":"Cefiderocol treatment for patients with multidrug- and carbapenem-resistant Pseudomonas aeruginosa infections in the compassionate use program","volume":"67","author":"Satlin","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"B49","doi-asserted-by":"publisher","first-page":"11700","DOI":"10.1038\/s41598-021-90732-3","article-title":"Effects of colistin and tigecycline on multidrug-resistant Acinetobacter baumannii biofilms: advantages and disadvantages of their combination","volume":"11","author":"Sato","year":"2021","journal-title":"Sci. Rep."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1584655","article-title":"Corrigendum: Understanding the burden of antibiotic resistance: a decade of carbapenem-resistant Gram-negative bacterial infections in Italian intensive care units","volume":"16","author":"Scaglione","year":"2025","journal-title":"Front. Microbiol."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11081136","article-title":"In vitro activity of sulbactam\u2013durlobactam against carbapenem-resistant Acinetobacter baumannii clinical isolates: a multicentre report from Italy","volume":"11","author":"Segatore","year":"2022","journal-title":"Antibiotics"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.1068840","article-title":"Susceptibility profile of blaOXA-23 and metallo-\u03b2-lactamases co-harbouring isolates of carbapenem resistant Acinetobacter baumannii (CRAB) against standard drugs and combinations","volume":"12","author":"Sharma","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioflm.2024.100222","article-title":"Staphylococcus aureus colonizing the skin microbiota of adults with severe atopic dermatitis exhibits genomic diversity and convergence in biofilm traits","volume":"8","author":"Sivori","year":"2024","journal-title":"Biofilm"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01683-24","article-title":"Biofilm-mediated antibiotic tolerance in Staphylococcus aureus from spinal cord stimulation device-related infections","volume":"12","author":"Sivori","year":"2024","journal-title":"Microbiol. Spectr"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00617-23","article-title":"Role of transcriptomic and genomic analyses in improving the comprehension of cefiderocol activity in Acinetobacter baumannii","volume":"9","author":"Stracquadanio","year":"2024","journal-title":"mSphere"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s10096-024-04831-w","article-title":"In vitro activity of cefiderocol against carbapenem-resistant Acinetobacter baumannii carrying various \u03b2-lactamase encoding genes","volume":"43","author":"Uskudar-Guclu","year":"2024","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03061-22","article-title":"Phenotypic characterization and heterogeneity among modern clinical isolates of Acinetobacter baumannii","volume":"11","author":"Valcek","year":"2023","journal-title":"Microbiol. Spectr"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.2147\/IDR.S407577","article-title":"Genomic\u00a0determinants of pathogenicity and antimicrobial resistance of nosocomial\u00a0Acinetobacter baumannii clinical isolates of hospitalized patient, (2019\u20132021) from a sentinel hospital in Hangzhou, China","volume":"16","author":"Wei","year":"2023","journal-title":"IDR"},{"key":"B59","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.tim.2021.11.008","article-title":"Acinetobacter baumannii","volume":"30","author":"Whiteway","year":"2022","journal-title":"Trends Microbiol."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12112532","article-title":"Cefiderocol in combating carbapenem-resistant Acinetobacter baumannii: action and resistance","volume":"12","author":"Yousefi","year":"2024","journal-title":"Biomedicines"},{"key":"B61","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1186\/s12879-021-06529-2","article-title":"Comparative analysis of carbapenemases, RND family efflux pumps and biofilm formation potential among Acinetobacter baumannii strains with different carbapenem susceptibility","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Infect. Dis."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1788718\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:36:03Z","timestamp":1776144963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1788718\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":61,"alternative-id":["10.3389\/fcimb.2026.1788718"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1788718","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"article-number":"1788718"}}